secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2022-12-15T23:59:59+00:00
Accession:  0001193125-22-305076
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium amends merger disclosures following three Metacrine stockholder lawsuits
--------------------------------------------------------------------------------

- Three lawsuits filed by Metacrine stockholders challenge disclosures in joint proxy for merger with Equillium.
- Equillium and Metacrine voluntarily supplement proxy with new details on deal background, valuation analyses, and projections.
- Supplement includes corrected PIPE study data, revised comparable company analysis, and updated discounted cash flow projections.
- Initial proposal valued Metacrine at ~$28M; final offer of $37.5M all-stock plus CVRs up to $22.5M for MET642 milestones.
- Companies deny allegations but add disclosures to avoid nuisance and delay; no admission of materiality.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312522305076/0001193125-22-305076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312522305076/d429598d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-305076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer